Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Divvyup, thanks for the IOT Superview from MS - how do you see that working for SYME by supplier / customer type, by product type, by country by warehouse? Have MS, Oracle or Amazon been able to do this to date ie all products are IOT into/out of inventory yet? NO But SYME will do it? Even if possible the effort behind it is ephemeral / out dated.
Try to tie that with a slow, slow crunching transactional blockchain and there may be more unnecessary delays?
l'll chip in
crl23 seems like you have fought yourself into a void - just stay there.
Zero SP appreciation over the year, big salaries and bonuses & LTIP paid but little skin in the game from BOD and more funding required as per RNS: Diurnal expects its cash resources to take its core commercial European cortisol deficiency franchise through to profitability based upon current plans and assumptions, including expectations regarding the timing of product approvals and sales projections. The Group intends to 'ringfence' this franchise and to seek incremental funding and/or partnering arrangements for discrete, future development opportunities. These plans assume that Diurnal enters into a licensing agreement for the commercialisation of Efmody® in the US, and does not include the potential for investment in DITEST™ Phase 3 clinical development and/or Efmody® US studies in adrenal insufficiency, which could require additional financing being available to the Group if the Group was unable to self-finance these activities through its operating cashflows, through additional equity investment, non-dilutive financing and/or partnering arrangements.
The BOD needs to start delivering - they have not even put the full accounts up on their site for scruntiny - taking PI for a cash ride!
Zero SP appreciation over the year, big salaries and bonuses & LTIP paid but little skin in the game from BOD and more funding required as per RNS: Diurnal expects its cash resources to take its core commercial European cortisol deficiency franchise through to profitability based upon current plans and assumptions, including expectations regarding the timing of product approvals and sales projections. The Group intends to 'ringfence' this franchise and to seek incremental funding and/or partnering arrangements for discrete, future development opportunities. These plans assume that Diurnal enters into a licensing agreement for the commercialisation of Efmody® in the US, and does not include the potential for investment in DITEST™ Phase 3 clinical development and/or Efmody® US studies in adrenal insufficiency, which could require additional financing being available to the Group if the Group was unable to self-finance these activities through its operating cashflows, through additional equity investment, non-dilutive financing and/or partnering arrangements.
The BOD needs to start delivering - they have not even put the full accounts up on their site for scruntiny - taking PI for a cash ride!
Noy quite seeing the upside you see, looks like one of DW mates - Interim Chief Financial Accountant BOE
https://uk.linkedin.com/in/david-bull-1688a25